✦ LIBER ✦

PP-8-5 A randomised study assessing oestrogen suppression with arimidex™ (Anastrozole) and formestane in postmenopausal advanced breast cancer (ABC) patients

✍ Scribed by M. Dowsett; D.A. Vorobiof; U.R. Kleeberg; R.P. Carrion; D.J. Dodwell; J.F.R. Robertson; L Calvo

Book ID: 116168221
Publisher: Elsevier Science
Year: 1996
Tongue: English
Weight: 358 KB
Volume: 32
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(96)84240-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Biological study of anastrozole in post-

Biological study of anastrozole in post-menopausal advanced breast cancer (ABC) patients: Effects on bone metabolism and oestrogen suppression

✍ A. Martinetti; E. Bajetta; R. Buzzoni; N. Zilembo; L. Ferrari; P. Pozzi; S.C. St 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 195 KB

PP-8-3 Double-blind trial in postmenopau

PP-8-3 Double-blind trial in postmenopausal (PMP) women with advanced breast cancer (ABC) showing a dose-effect and superiority of 2.5 mg letrozole over megestrol acetate (MA)

✍ I. Smith; P. Dombemowsky; G. Falkson; R. Leonard; L. Panasci; J. Bellmunt; W. Be 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 182 KB

Doxorubicin versus methotrexate both com

Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer—a randomised study with more than 10 years follow-up from the danish breast cancer cooperative group

✍ M Andersson; E Lindegaard Madsen; M Overgaard; C Rose; P Dombernowsky; H.T Mouri 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 117 KB

Doxorubicin versus methotrexate both com

✍ M Andersson; E Lindegaard Madsen; M Overgaard; C Rose; P Dombernowsky; H.T Mouri 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 117 KB

To evaluate the substitution of methotrexate with doxorubicin (Dox) in CMF-(cyclophosphamide, methotrexate, 5-fluorouracil) containing regimen for advanced breast cancer, 415 postmenopausal patients below the age of 66 years, naïve to chemotherapy, were accrued from 1980 to 1984 and followed-up unti